Blocking inflammation on the way: Rationale for CXCR2 antagonists for the treatment of COVID-19

Koenig, L. M., Boehmer, D. F. R., Metzger, P., Schnurr, M., Endres, S., and Rothenfusser, S. (2020). J Exp Med 217


An exacerbated and unbalanced immune response may account for the severity of COVID-19, the disease caused by the novel severe acute respiratory syndrome (SARS) coronavirus 2, SARS-CoV-2. In this Viewpoint, we summarize recent evidence for the role of neutrophils in the pathogenesis of COVID-19 and propose CXCR2 inhibition as a promising treatment option to block neutrophil recruitment and activation.